Elixxer Ltd. (ELIXF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $3.19M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerElixxer Ltd. (ELIXF) trades at $0.0335. Elixxer Ltd. is a cannabis investment firm operating in multiple international markets. Market cap: $3.19M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for ELIXF: ELIXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ELIXF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
ELIXF: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Elixxer Ltd. (ELIXF) Healthcare & Pipeline Overview
Elixxer Ltd. is a Canadian cannabis investment firm with a global footprint, focusing on licensed cultivation, production, and sale of medical and specialty cannabis. Operating in a fragmented and evolving regulatory landscape, Elixxer seeks strategic investments in key international markets within the specialty and generic drug sector.
What Is the Investment Thesis for ELIXF?
Elixxer Ltd. presents a speculative investment opportunity within the evolving cannabis industry. With a market capitalization of $3.19M and a negative P/E ratio of -0.15, the company's valuation reflects its current stage of development and profitability challenges. Key value drivers include the growth of the global cannabis market and the successful execution of Elixxer's investment strategy in licensed cannabis businesses. Upcoming catalysts include potential regulatory changes in key markets and the expansion of Elixxer's portfolio through strategic acquisitions. However, potential risks include regulatory uncertainty, competition from larger players in the pharmaceutical sector, and the company's reliance on the performance of its portfolio companies.
Based on FMP financials and quantitative analysis
ELIXF Key Highlights
Market Cap of $3.19M indicates a micro-cap company with high growth potential but also higher risk.
- Negative P/E ratio of -0.15 reflects current unprofitability, requiring careful monitoring of future earnings potential.
- Beta of -0.54 suggests a negative correlation with the market, potentially offering diversification benefits during market downturns.
- Operates in the rapidly growing cannabis industry, presenting significant growth opportunities.
- Geographic diversification across Canada, Australia, Italy, Jamaica, and Switzerland mitigates regulatory risks.
Who Are ELIXF's Competitors?
ELIXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CANSF Atlas Energy Corp. | $0.08 | -7.66% | $27.6M | — |
| CXXIF C21 Investments Inc. | $0.26 | -0.11% | $31.4M | — |
| MILFF 1CM Inc. | $0.22 | 0.00% | $26.3M | — |
| AVCNF Avicanna Inc. | $0.08 | 0.00% | $10.6M | 529-signal |
| PLNH Planet 13 Holdings Inc. | $0.13 | -7.14% | $42.7M | 429-signal |
| DBCCF Decibel Cannabis Company Inc. | $1.27 | -3.39% | $49.0M | 459-signal |
| ZYBT Zhengye Biotechnology Holding Limited | $1.59 | +1.27% | $75.4M | 465-pillar |
| CWBHF Charlotte's Web Holdings, Inc. | $0.33 | -3.93% | $88.4M | 519-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are ELIXF's Key Strengths?
Diversified geographic presence.
- Focus on licensed cannabis businesses.
- Experienced management team.
- Early mover advantage in select markets.
What Are ELIXF's Weaknesses?
Small market capitalization.
- Negative profitability.
- Reliance on portfolio company performance.
- Limited financial resources.
What Could Drive ELIXF Stock Higher?
ELIXF catalyst: Potential regulatory changes in key markets, such as Canada and Australia, could create new opportunities for Elixxer's portfolio companies.
- Expansion of the global cannabis market, driven by increasing legalization and acceptance, is expected to fuel growth for Elixxer's investments.
- Strategic acquisitions and partnerships could enhance Elixxer's market presence and expand its portfolio of cannabis businesses.
- Development of new cannabis-based therapies and products by Elixxer's portfolio companies could drive revenue growth and increase shareholder value.
What Are the Key Risks for ELIXF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory uncertainty and changes in cannabis laws could negatively impact Elixxer's investments.
- Competition from larger players in the pharmaceutical and cannabis industries could limit Elixxer's market share and profitability.
- Fluctuations in cannabis prices and changes in consumer preferences could affect the performance of Elixxer's portfolio companies.
- The company's reliance on the performance of its portfolio companies exposes it to risks associated with their individual operations and financial health.
What Are the Growth Opportunities for ELIXF?
- Expansion into New Therapeutic Areas: Elixxer can explore opportunities to invest in cannabis businesses focused on developing novel therapies for specific medical conditions. The global market for cannabis-based pharmaceuticals is projected to reach $5.8 billion by 2028, driven by increasing clinical research and regulatory approvals. Elixxer's expertise in identifying and supporting licensed cannabis businesses can provide a competitive advantage in this rapidly growing market. Timeline: Ongoing.
- Strategic Acquisitions and Partnerships: Elixxer can pursue strategic acquisitions and partnerships to expand its portfolio of cannabis businesses and enhance its market presence. The cannabis industry is undergoing consolidation, with larger companies acquiring smaller players to gain market share and access new technologies. Elixxer can leverage its investment expertise and industry network to identify attractive acquisition targets and forge strategic partnerships. Timeline: Ongoing.
- Geographic Expansion into Emerging Markets: Elixxer can expand its geographic footprint by investing in cannabis businesses in emerging markets with favorable regulatory environments. The global cannabis market is expanding beyond North America and Europe, with new markets opening up in Latin America, Asia, and Africa. Elixxer's experience in navigating international regulatory frameworks can provide a competitive advantage in these emerging markets. Timeline: 2026-2028.
- Development of Value-Added Cannabis Products: Elixxer can invest in cannabis businesses focused on developing value-added products, such as edibles, topicals, and concentrates. These products offer higher margins and greater consumer appeal compared to traditional cannabis flower. The market for value-added cannabis products is growing rapidly, driven by changing consumer preferences and increasing product innovation. Timeline: Ongoing.
- Investment in Cannabis Technology and Innovation: Elixxer can invest in cannabis technology and innovation companies focused on developing new cultivation techniques, extraction methods, and product formulations. These technologies can improve efficiency, reduce costs, and enhance product quality. The market for cannabis technology is growing rapidly, driven by increasing demand for innovative solutions. Timeline: Ongoing.
What Are ELIXF's Competitive Advantages?
- Expertise in navigating international cannabis regulations.
- Established network of licensed cannabis businesses.
- Early mover advantage in select international markets.
What Does ELIXF Do?
Elixxer Ltd., formerly known as LGC Capital Ltd., is a cannabis investment firm established in 2004 and headquartered in Montreal, Canada. The company strategically invests in cannabis-related businesses across multiple international markets, including Canada, Australia, Italy, Jamaica, and Switzerland. These businesses are fully licensed for the cultivation, production, and/or sale of medical and specialty cannabis and cannabis-derived products, primarily within the pharmaceutical sector. Elixxer's investment approach centers on identifying and supporting companies that operate within legally regulated cannabis markets. The company aims to capitalize on the growing global demand for medical and specialty cannabis products by providing capital and expertise to its portfolio companies. Elixxer's evolution from LGC Capital Ltd. to its current focus reflects the shifting landscape of the cannabis industry and the company's strategic adaptation to emerging opportunities in the sector. The company's diversified geographic presence allows it to mitigate risks associated with regulatory changes in any single market.
What Products and Services Does ELIXF Offer?
- Invests in cannabis-related businesses.
- Focuses on companies with licenses for cultivation.
- Supports businesses involved in cannabis production.
- Targets companies selling medical cannabis.
- Invests in firms selling specialty cannabis products.
- Operates in Canada, Australia, Italy, Jamaica, and Switzerland.
How Does ELIXF Make Money?
- Invests capital in cannabis companies.
- Seeks returns through equity appreciation and potential dividends.
- Focuses on licensed businesses to minimize regulatory risk.
What Industry Does ELIXF Operate In?
Elixxer Ltd. operates within the rapidly expanding cannabis industry, which is experiencing significant growth driven by increasing legalization and acceptance of cannabis for medical and recreational purposes. The market is characterized by a fragmented competitive landscape, with numerous companies vying for market share. Elixxer's focus on investing in licensed cannabis businesses positions it within the specialty and generic drug manufacturing segment of the healthcare sector. The company faces competition from established pharmaceutical companies, as well as other cannabis-focused investment firms. The industry is subject to evolving regulatory frameworks, which can significantly impact market dynamics and business operations.
Who Are ELIXF's Key Customers?
- Cannabis cultivation companies seeking capital.
- Cannabis production facilities requiring investment.
- Licensed medical cannabis businesses needing funding.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 254 days ago
- ● No analyst coverage
- ● Reported in CAD, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 48 |
| 2026-08-26 | 48 |
| 2026-08-29 | 48 |
| 2026-09-01 | 48 |
| 2026-09-04 | 48 |
| 2026-09-07 | 48 |
| 2026-09-10 | 48 |
What changed?
The score has stayed at 48.
Over the same 18 days the stock moved +0.0%.
Financial Health
Elixxer Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Elixxer Ltd. stands at 29.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -15.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Elixxer Ltd. (ELIXF) Valuation Context
Valued at $3.19M, ELIXF is classified as a micro-cap stock.
ELIXF Revenue & Earnings Trend
In Q4 FY2025, ELIXF generated $0 in top-line revenue. The company recorded a net loss of $1.4M, with diluted EPS of $-0.12. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ELIXF averaged $-0.06 in diluted EPS.
Company Profile
Elixxer Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, Canada.
ELIXF Financials
Bull Case vs Bear Case
Bull Case
- Diversified geographic presence.
- Focus on licensed cannabis businesses.
- Experienced management team.
- Early mover advantage in select markets.
Bear Case
- Small market capitalization.
- Negative profitability.
- Reliance on portfolio company performance.
- Limited financial resources.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 FY2025 | $0 | -$1M | -$0.12 |
| Q3 FY2025 | $0 | -$557,695.53 | -$0.05 |
| Q2 FY2025 | $0 | -$446,662.911 | -$0.04 |
| Q1 FY2025 | $0 | -$392,962.641 | -$0.03 |
Q4 FY2025 · filed 31 Dec 2025 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from CAD at today's rate
ELIXF Latest News
-
Elixxer Announces Amending Agreement
newsfilecorp.com · Sep 9, 2026
-
Elixxer Announces Adoption of Semi-Annual Reporting
Yahoo! Finance: ELIXF News · May 1, 2026
-
Elixxer Provides Update on Secured and Unsecured Loans
Yahoo! Finance: ELIXF News · Feb 2, 2026
-
Elixxer Announces Completion of Debt Settlement
Yahoo! Finance: ELIXF News · Jan 14, 2026
ELIXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ELIXF.
Price Targets
Wall Street price target analysis for ELIXF.
ELIXF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ELIXF; grades run from A+ (80-100) to F (below 30).
Latest News
Elixxer Announces Amending Agreement
Elixxer Announces Adoption of Semi-Annual Reporting
Elixxer Provides Update on Secured and Unsecured Loans
Elixxer Announces Completion of Debt Settlement
Leadership: Karim Mecklai
CEO
Karim Mecklai is the CEO of Elixxer Ltd. His background includes experience in finance and investment management, with a focus on emerging markets. He has held various leadership positions in the financial services industry, including roles in investment banking and private equity. His expertise lies in identifying and evaluating investment opportunities, structuring deals, and managing portfolio companies. Mecklai's experience in emerging markets is particularly relevant to Elixxer's international operations.
Track Record: Under Karim Mecklai's leadership, Elixxer Ltd. has focused on expanding its investment portfolio in licensed cannabis businesses across multiple international markets. Key milestones include strategic investments in cannabis cultivation, production, and retail operations in Canada, Australia, Italy, Jamaica, and Switzerland. Mecklai has also overseen the company's rebranding from LGC Capital Ltd. to Elixxer Ltd., reflecting its strategic shift towards the cannabis industry.
ELIXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Elixxer Ltd. may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information availability and increased price volatility. This tier is often populated by shell companies, bankrupt entities, or companies with questionable operations.
- OTC Tier: OTC Other
- Limited regulatory oversight compared to major exchanges.
- Potential for information asymmetry and lack of transparency.
- Higher price volatility and potential for manipulation.
- Limited liquidity and difficulty executing large trades.
- Increased risk of fraud or mismanagement.
- Verify the company's legal status and registration.
- Independently audit available financial statements.
- Research the background and experience of management.
- Assess the company's business model and competitive landscape.
- Evaluate the company's compliance with relevant regulations.
- Monitor news and filings for any red flags.
- Consult with a qualified financial advisor.
- Operations in multiple countries (Canada, Australia, Italy, Jamaica, and Switzerland).
- Focus on licensed cannabis businesses.
- Experienced CEO with a background in finance and investment management.
- Company was incorporated in 2004.
Common Questions About ELIXF (Healthcare)
Is ELIXF a good stock?
Stock Expert AI does not rate ELIXF buy, sell or hold. Elixxer Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about ELIXF stock?
As of March 17, 2026, there is no readily available analyst consensus on Elixxer Ltd. (ELIXF) due to its OTC listing and small market capitalization.
What are the key factors to evaluate for ELIXF?
Evaluate ELIXF on fundamentals, analyst consensus, and risk factors. Market Cap of $3.19M indicates a micro-cap company with high growth potential but also higher risk. Not financial advice.
How frequently does ELIXF data refresh on this page?
ELIXF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ELIXF's recent stock price performance?
Elixxer Ltd. (ELIXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified geographic presence. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ELIXF overvalued or undervalued right now?
Elixxer Ltd. (ELIXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ELIXF?
Yes, most major brokerages offer fractional shares of Elixxer Ltd. (ELIXF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ELIXF's earnings and financial reports?
Elixxer Ltd. (ELIXF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ELIXF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing and small market capitalization.
- Financial data may not be fully audited or verified.